Evaluation of the test-retest and inter-mode comparability of the Impact of Vision Impairment questionnaire in people with chronic eye diseases.

Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 8205248 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1435-702X (Electronic) Linking ISSN: 0721832X NLM ISO Abbreviation: Graefes Arch Clin Exp Ophthalmol Subsets: MEDLINE

Original Publication: Berlin ; New York : Springer-Verlag, c1982-

Quality of Life* ; Psychometrics*/methods ; Sickness Impact Profile*; Humans ; Male ; Female ; Reproducibility of Results ; Aged ; Chronic Disease ; Surveys and Questionnaires ; Patient Reported Outcome Measures ; Eye Diseases/diagnosis ; Vision Disorders/diagnosis ; Vision Disorders/physiopathology ; Vision Disorders/psychology ; Visual Acuity ; Middle Aged ; Visually Impaired Persons/psychology

Purpose: The main objective of this study is to assess the test-retest and inter-administration mode reliability of the Impact of Vision Impairment profile (IVI), a common patient-reported outcome measure (PROM) for people with chronic eye diseases.
Methods: The IVI was administered to adult patients with stable, chronic eye diseases two to four times per participant (average intervals between administrations 12 to 20 days; maximum two phone interviews, paper administration, electronic administration) by two trained interviewers. Rasch models were fit to the data. Intra-class correlation coefficients (ICCs), mean differences and Cronbach's alpha between test-retest administrations (two phone interviews) and inter-mode comparisons were calculated.
Results: Two hundred-sixteen patients (mean age 67 ± 12 years, 40% male) were included in the study. The IVI met all psychometric requirements of the Rasch model, and the division into the domains of functional items (IVI_F) and emotional items (IVI_E) corresponded to the German validation study. ICCs (all for IVI_F and IVI_E, respectively) for the retest administrations were 0.938 and 0.912, and 0.853 and 0.893 for inter-mode comparisons phone/paper, 0.939 and 0.930 for phone/electronic, and 0.937 and 0.920 for paper/electronic (all p < 0.01). Mean differences (all for IVI_F and IVI_E, respectively) for the retest administrations were 2.8% and 0.7% and ranged from 2.0% to 6.2% and from 0.4 % to 4.9% between administration modes. Cronbach's alpha ranged from 0.886 to 0.944 for retest and inter-mode comparisons.
Conclusion: Due to the high test-retest reliability and the almost equally high comparability of different modes of administration of the IVI, the study endorses its use as a robust PROM to capture vision-related quality of life. Our results further support the use of the IVI as an endpoint in clinical trials and may simplify implementing it in both clinical trials or real-world evidence generation by offering multiple administration modes with high reliability.
(© 2024. The Author(s).)

Lancet. 1986 Feb 8;1(8476):307-10. (PMID: 2868172)
Ophthalmic Epidemiol. 2001 Feb;8(1):1-11. (PMID: 11262678)
Optom Vis Sci. 2007 Aug;84(8):789-96. (PMID: 17700342)
Ophthalmology. 2013 Oct;120(10):2151-9. (PMID: 23714321)
Ophthalmology. 2006 Oct;113(10):1846-53. (PMID: 16889831)
Transl Vis Sci Technol. 2018 Dec 28;7(6):38. (PMID: 30619658)
Aust N Z J Ophthalmol. 1999 Jun-Aug;27(3-4):184-6. (PMID: 10484186)
BMJ Open Ophthalmol. 2021 Jun 15;6(1):e000693. (PMID: 34212114)
PLoS One. 2016 May 18;11(5):e0155509. (PMID: 27191960)
Am J Ment Defic. 1981 Sep;86(2):127-37. (PMID: 7315877)
J Bone Miner Res. 2004 Sep;19(9):1539-47. (PMID: 15312256)
Invest Ophthalmol Vis Sci. 2007 Apr;48(4):1476-82. (PMID: 17389474)
Br J Ophthalmol. 2017 Jun;101(6):700-708. (PMID: 28455280)
Cogn Psychol. 2021 Aug;128:101406. (PMID: 34214734)
Arch Ophthalmol. 1995 Dec;113(12):1508-13. (PMID: 7487617)
J Chiropr Med. 2016 Jun;15(2):155-63. (PMID: 27330520)
Invest Ophthalmol Vis Sci. 2011 Jun 01;52(6):3613-9. (PMID: 21357395)
Ophthalmology. 2014 Jun;121(6):1246-51. (PMID: 24518613)
Clin Exp Optom. 2020 Nov;103(6):733-741. (PMID: 32128871)
Graefes Arch Clin Exp Ophthalmol. 2008 Apr;246(4):477-82. (PMID: 18071740)
Cornea. 2019 May;38(5):600-604. (PMID: 30730335)
BMC Ophthalmol. 2008 Mar 06;8:4. (PMID: 18325083)
Value Health. 2007 Nov-Dec;10 Suppl 2:S94-S105. (PMID: 17995479)
Cornea. 2002 Aug;21(6):578-83. (PMID: 12131034)
Sci Rep. 2019 Oct 25;9(1):15326. (PMID: 31653904)
Br J Ophthalmol. 2023 Aug;107(8):1144-1150. (PMID: 35354561)
PLoS One. 2013 Sep 09;8(9):e73990. (PMID: 24040139)
Invest Ophthalmol Vis Sci. 2006 Nov;47(11):4732-41. (PMID: 17065481)
Ophthalmic Physiol Opt. 2004 Jul;24(4):257-73. (PMID: 15228503)
J Appl Meas. 2019;20(2):154-166. (PMID: 31120433)
Eur J Ophthalmol. 2022 Jan;32(1):481-490. (PMID: 33213182)
Transl Vis Sci Technol. 2022 Apr 1;11(4):21. (PMID: 35446409)
BMJ. 2015 Feb 10;350:g7818. (PMID: 25670183)
Br J Ophthalmol. 2006 May;90(5):593-6. (PMID: 16622089)
Patient Relat Outcome Meas. 2019 Jan 24;10:9-24. (PMID: 30774489)
Value Health. 2008 Mar-Apr;11(2):322-33. (PMID: 18380645)
Arch Phys Med Rehabil. 1989 Nov;70(12):857-60. (PMID: 2818162)
Transl Vis Sci Technol. 2020 Jul 16;9(8):25. (PMID: 32864194)
Biochem Med (Zagreb). 2015 Jun 05;25(2):141-51. (PMID: 26110027)
Invest Ophthalmol Vis Sci. 2002 Apr;43(4):927-35. (PMID: 11923230)
Health Technol Assess. 2009 Feb;13(12):iii, ix-x, 1-177. (PMID: 19216837)
Clin Ophthalmol. 2019 May 03;13:795-803. (PMID: 31118557)
Clin Exp Ophthalmol. 2000 Jun;28(3):156-61. (PMID: 10981786)
Br J Ophthalmol. 2000 Sep;84(9):1035-40. (PMID: 10966961)
Surv Ophthalmol. 2001 May-Jun;45(6):531-48. (PMID: 11425359)

Keywords: Impact of Vision Impairment scale; Patient-reported outcome; Quality of life; Reliability

Date Created: 20240105 Date Completed: 20240520 Latest Revision: 20240523

20240523

PMC11106107

10.1007/s00417-023-06334-4

38180569